For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB0214Ja&default-theme=true
RNS Number : 0214J Byotrol PLC 02 April 2024
Byotrol Plc
("Byotrol" or the "Company")
Director Dealing
Byotrol Plc (AIM: BYOT), the specialist infection prevention and control
company, announces that, on 2(nd) April 2024, David Traynor, Interim CEO of
the Company, purchased a total of 2,808,326 ordinary shares of 0.25p each
("Ordinary Shares") at an average price of 0.134p per Ordinary Share (the
"Purchase").
Following the Purchase, Mr. Traynor's beneficial holding is 12,743,623
Ordinary Shares, representing 2.8% of the total voting rights of the Company.
As announced on 28 July 2022, Mr. Traynor subscribed for convertible loan
notes in the Company, which if converted would represent an additional 0.34%
of the total voting rights of the Company.
For further information contact:
Byotrol Plc
Dr Trevor Francis, Non- Executive Chairman +44 (0)1925 742 000
David Traynor, Interim Chief Executive Officer
Chris Sedwell, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Broker) +44 (0)20 7220 0500
Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Flagstaff Strategic and Investor Communications +44 (0)20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)
The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the animal and human healthare,
industrial, institutional and consumer sectors, providing low toxicity
products with a broad-based and targeted efficacy across all microbial
classes; bacteria, viruses (including coronavirus), fungi, moulds,
mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.
Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.
For more information, go to byotrol.com
The Notification of Dealing Form set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name David Traynor
2. Reason for the Notification
a) Position/status Interim Chief Executive Officer
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Byotrol plc
b) LEI 213800AJMTSTIPA59A34
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 0.25 pence per share
Identification code GB00B0999995
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
0.134p 2,808,326
d) Aggregated information:
·Aggregated volume See 4c) above
· Price
e) Date of the transaction 2 April 2024
f) Place of the transaction AIM, London Stock Exchange (XLON)
d)
Aggregated information:
·Aggregated volume
· Price
See 4c) above
e)
Date of the transaction
2 April 2024
f)
Place of the transaction
AIM, London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZZGGDDZDGDZM